



Sierra Oncology (USA): Constituent Deletion Changes in Russell Equal Weight Index Series

30 June 2022

Subject to the completion of the cash acquisition for Sierra Oncology (USA, constituent) by GSK plc, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	6 July 2022*

*In the absence of an active trading market, Sierra Oncology will be removed from the index at the cash acquisition terms of 55.00 USD per each share held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1440
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2022 FTSE Russell